Zum Hauptinhalt springen
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Phase 2325 Teilnehmende gesucht75 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Erkrankungen

  • Major Depressive Disorder

Eignung

Eignung
GeschlechtAlle
Alter18 Years – 70 Years
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 2
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme325 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Alto Neuroscience Sponsor

Studienarme und Interventionen

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

Interventionen

  • Arzneimittel ALTO-300

    ALTO-300 capsule QD

  • Arzneimittel Placebo

    Placebo capsule QD

Endpunkte

  1. Primärer Endpunkt

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Zeitrahmen Change over time for up to week 6

  2. Sekundärer Endpunkt

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Zeitrahmen Change over time for up to week 6

  3. Sekundärer Endpunkt

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Zeitrahmen Change over time for up to week 6

  4. Sekundärer Endpunkt

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    Zeitrahmen Assessed from Day 1 to Week 14

  5. Sekundärer Endpunkt

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    Zeitrahmen Assessed from Day 1 to Week 14

  6. Sekundärer Endpunkt

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    Zeitrahmen Assessed from Day 1 to Week 14

  7. Sekundärer Endpunkt

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    Zeitrahmen Assessed from Day 1 to Week 14

  8. Sekundärer Endpunkt

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    Zeitrahmen Assessed from Day 1 to Week 15

Daten

Daten
Startdatum8. Juni 2023 (tatsächlich)
Primärer Abschluss1. Dezember 2026 (geschätzt)
Abschluss1. Dezember 2026 (geschätzt)
Erstveröffentlichung28. Juni 2023 (tatsächlich)
Zuletzt aktualisiert26. Oktober 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtOktober 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

30 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Site 114AlbuquerqueNew MexicoRekrutiert
Site 216AllentownPennsylvaniaVorzeitig beendet
Site 316AustinTexasRekrutiert
Site 218BellflowerCaliforniaRekrutiert
Site 317BlackfootIdahoZurückgezogen
Site 236BoiseIdahoRekrutiert
Site 119BoiseIdahoAktiv, rekrutiert nicht
Site 318CarlsbadCaliforniaAktiv, rekrutiert nicht
Site 310ChicagoIllinoisAktiv, rekrutiert nicht
Site 202CincinnatiOhioRekrutiert
Site 159ClermontFloridaVorzeitig beendet
Site 207ClintonUtahAktiv, rekrutiert nicht
Site 203Colorado SpringsColoradoAktiv, rekrutiert nicht
Site 239ConroeTexasRekrutiert
Site 229Creve CouerMissouriZurückgezogen
Site 102DallasTexasAktiv, rekrutiert nicht
Site 343DenverColoradoRekrutiert
Site 349EvergreenColoradoAktiv, rekrutiert nicht
Site 345EvergreenColoradoAktiv, rekrutiert nicht
Site 277FairfaxVirginiaRekrutiert
Site 238FayettevilleGeorgiaRekrutiert
Site 148Fort WorthTexasZurückgezogen
Site 347Fort WorthTexasVorzeitig beendet
Site 217GlendaleCaliforniaAktiv, rekrutiert nicht
Site 279HattiesburgMississippiZurückgezogen
Site 199HickoryNorth CarolinaAktiv, rekrutiert nicht
Site 320HoustonTexasRekrutiert
Site 275HoustonTexasRekrutiert
Site 215JacksonMississippiAktiv, rekrutiert nicht
Site 335LafayetteCaliforniaRekrutiert
Site 335LafayetteCaliforniaRekrutiert
Site 344Las VegasNevadaRekrutiert
Site 209Los AngelesCaliforniaAktiv, rekrutiert nicht
Site 240MankatoMinnesotaRekrutiert
Site 201MarreroLouisianaVorzeitig beendet
Site 219MatherCaliforniaRekrutiert
Site 350MediaPennsylvaniaZurückgezogen
Site 225Miami GardensFloridaAktiv, rekrutiert nicht
Site 190Miami LakesFloridaAktiv, rekrutiert nicht
Site 265MinneapolisMinnesotaRekrutiert
Site 194Mission ViejoCaliforniaVorzeitig beendet
Site 206Missouri CityTexasZurückgezogen
Site 198MonroeLouisianaVorzeitig beendet
Site 267MoorparkCaliforniaRekrutiert
Site 352MoosicPennsylvaniaAktiv, rekrutiert nicht
Site 283New YorkNew YorkRekrutiert
Site 319New YorkNew YorkAktiv, rekrutiert nicht
Site 214NorwalkConnecticutZurückgezogen
Site 161OkeechobeeFloridaAktiv, rekrutiert nicht
Site 195Oklahoma CityOklahomaVorzeitig beendet

25 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 26. Oktober 2026

    Teilnahmeziel geändert

    Enrollment target revised up from 321 to 325

    321325

  2. 26. Oktober 2026

    Studienzentrum hinzugefügt

    30 sites added (75 total)

    4575